131 related articles for article (PubMed ID: 10478643)
1. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Gratama JW; Zea AH; Bolhuis RL; Ochoa AC
Cancer Immunol Immunother; 1999 Aug; 48(5):263-9. PubMed ID: 10478643
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.
Riccobon A; Gunelli R; Ridolfi R; De Paola F; Flamini E; Fiori M; Saltutti C; Petrini M; Fiammenghi L; Stefanelli M; Granato AM; Cuzzocrea DE; Amadori D
Cancer Invest; 2004; 22(6):871-7. PubMed ID: 15641485
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
4. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Franco JL; Ghosh P; Wiltrout RH; Carter CR; Zea AH; Momozaki N; Ochoa AC; Longo DL; Sayers TJ; Komschlies KL
Cancer Res; 1995 Sep; 55(17):3840-6. PubMed ID: 7641202
[TBL] [Abstract][Full Text] [Related]
5. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
7. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
Bukowski RM; Olencki T; Wang Q; Peereboom D; Budd GT; Elson P; Sandstrom K; Tuason L; Rayman P; Tubbs R; McLain D; Klein E; Novick A; Finke J
J Immunother; 1997 Jul; 20(4):301-11. PubMed ID: 9220320
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
12. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Finke JH; Zea AH; Stanley J; Longo DL; Mizoguchi H; Tubbs RR; Wiltrout RH; O'Shea JJ; Kudoh S; Klein E
Cancer Res; 1993 Dec; 53(23):5613-6. PubMed ID: 8242613
[TBL] [Abstract][Full Text] [Related]
13. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
Whiteside TL
Adv Exp Med Biol; 1998; 451():167-71. PubMed ID: 10026868
[TBL] [Abstract][Full Text] [Related]
14. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
15. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
16. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.
Wersäll P; Mellstedt H
Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
[TBL] [Abstract][Full Text] [Related]
17. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.
De Paola F; Ridolfi R; Riccobon A; Flamini E; Barzanti F; Granato AM; Mordenti GL; Medri L; Vitali P; Amadori D
Br J Cancer; 2003 Jan; 88(2):320-6. PubMed ID: 12610520
[TBL] [Abstract][Full Text] [Related]
18. Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients.
Kim CW; Choi SH; Chung EJ; Lee MJ; Byun EK; Ryu MH; Bang YJ
Pathobiology; 1999; 67(3):123-8. PubMed ID: 10394132
[TBL] [Abstract][Full Text] [Related]
19. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
20. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
